Ondas (ONDS) stock slides again after J Capital report; Rotron deal and Singapore Airshow in focus
5 February 2026
2 mins read

Ondas (ONDS) stock slides again after J Capital report; Rotron deal and Singapore Airshow in focus

New York, February 5, 2026, 14:34 (EST) — Regular session

  • Ondas shares dropped roughly 9%, settling at $8.77 in afternoon trading, following a range between $8.56 and $9.80 earlier.
  • The stock plunged further following a bearish report from J Capital Research released the previous day
  • Ondas revealed an Asia-Pacific defense deal this week and struck a deal to acquire UK-based Rotron Aero

Shares of Ondas Inc took a hit on Thursday, dropping roughly 9% as the small-cap defense drone and wireless-networking firm continued its steep slide. By mid-afternoon, the Nasdaq-listed stock was trading down 9.4% at $8.77, with around 76 million shares changing hands.

The slide is significant given Ondas’s recent surge on rapid-fire deal news, leaving the tape jittery. Traders who pushed the stock up earlier this week are now questioning if new contract announcements can offset concerns over how the company will finance its growth.

The tension has taken center stage. Bulls want to see signed orders and delivery timelines, while skeptics focus on dilution — the selling of new shares that cuts into current investors’ stakes — and the risk that acquisitions might take a while to yield results.

J Capital Research, a self-described short-seller, released a note Wednesday titled “Ondas Won’t Live Up to the Hype.” It slammed Ondas’ strategy as “high-priced, money-losing acquisitions funded by massive share dilution,” accusing the company of “incinerating cash and value” while pointing to past fundraising rounds and insider sales. 1

Ondas shifted focus with news Tuesday that its Airobotics unit landed a “strategic” deal with a government defense client in the Asia-Pacific region. The contract covers autonomous unmanned aerial systems — drones — aimed at national security tasks. Initial deliveries are slated for this year, with potential follow-up orders. CEO Eric Brock noted demand in the area is “accelerating,” while OAS co-CEO Oshri Lugassy described the platforms as “combat proven.” 2

Ondas revealed the previous day that it had signed a definitive agreement to acquire Rotron Aero, a UK-based developer specializing in unmanned systems and long-range autonomous platforms. The deal involves a mix of cash and stock. Brock described the acquisition as a move that would “accelerate” Ondas’ drive toward full “end-to-end autonomous mission capability.” Corporate development head Mark Green added that the purchase would broaden the company’s presence in the UK and NATO markets. According to a Form 8-K filing, the deal is still pending customary conditions and regulatory approvals.

Ondas dropped 14.7% on Wednesday following the J Capital report, per Investing.com, with the downward pressure extending into Thursday. 3

Ondas highlighted its Asia-Pacific award at the Singapore Airshow, which continues through Feb. 8. Investors are eager for specifics on contract size, delivery timing, and if the company can secure additional orders while present in Singapore. 4

The downside scenario is straightforward. The Asia-Pacific deal didn’t reveal the customer or the dollar amount involved, and the Rotron deal hasn’t closed yet. Any regulatory hiccup, integration issues, or fresh fundraising round could keep the stock volatile.

Traders are now turning their attention to new updates from the Singapore Airshow before it closes on Sunday, along with any filings that clarify the timelines and details of the Rotron acquisition.

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
McDonald’s stock holds up as dividend date nears and leadership changes hit headlines
Previous Story

McDonald’s stock holds up as dividend date nears and leadership changes hit headlines

S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight
Next Story

S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight

Go toTop